Αρχική World News Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring... World News Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations Από Ogkologos - 10 Μαρτίου, 2026 401 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO 2024 Press Conference 13 Σεπτεμβρίου, 2024 FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... 18 Απριλίου, 2025 Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas 10 Ιουλίου, 2023 EMA Starts Review of Rucaparib 19 Μαΐου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab ESMO Clinical Practice Guideline Express Update on the management of epithelial... Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... Though the Pandemic Has Slowed, Many Are Still Struggling to Put...